First iPS Cell Trial Underway But A Long Way To Go
This article was originally published in PharmAsia News
Researchers in Japan have "dosed" the initial patient in the world's first clinical trial involving a regenerative therapy based on the country's flagship induced pluripotent stem (iPS) cell technology.
You may also be interested in...
Building on its national expertise in the area, Japan is starting the first clinical trial globally to assess the use of iPS-derived cells for the treatment of Parkinson’s disease.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.